Journey Biosciences launches NaviDKD™ for people with diabetes to predict long-term kidney complications
Ohio Pen/10202948

First and only scientifically-based screening technology provides an early read on the risk of developing kidney disease for people with diabetes, giving them and their doctors time to take preventative action and improve outcomes.

LEBANON, N.H., Dec. 1, 2022 /PRNewswire/ -- Journey Biosciences, Inc., a biotechnology company offering biomarker-based predictive risk screening technologies for diabetes-related complications, today announced the launch of its flagship product NaviDKD.

NaviDKD, a biomarker-based blood test, proactively assesses the risk of kidney disease in people with diabetes years before clinical signs or symptoms appear. Along with its proprietary Compass reporting platform, NaviDKD provides actionable insights for preventing and managing kidney complications before they occur.

More on Ohio Pen

• $20 Price Target in Noble Capital Research Report as Deal is Signed for NFL Yearbook Advertising Across 25 Stadiums for AI Powered Sports Leader $SEGG
• 3E Launches First AI Agent Designed to Respond with Empathy for College Recruitment
• Security Alert: TZNXG Warns Investors About "Fund Recovery" Scams
• Assent Unveils Extended Producer Responsibility Packaging Solution to Simplify Compliance with Expanding Packaging Laws
• KatalisCoin: "Too Secure" for Bad Actors - Platform Embraces "Excessive Compliance" Criticism

"For the one-in-three people with diabetes who will develop diabetic kidney disease, NaviDKD provides an opportunity to fundamentally change their ultimate health outcomes," said Adam Graybill, Chief Executive Officer of Journey Biosciences. "By identifying those at elevated or high risk of developing DKD before any symptoms or clinical indications, the conversation between doctor and patient can focus on taking proactive, preventative action instead of reacting to an unwanted diagnosis."

Journey Biosciences received CLIA certification for its lab in August 2022 and all NaviDKD blood samples are processed in this Cleveland, Ohio-based lab.

Both healthcare professionals and people with diabetes can learn more and request NaviDKD at www.journeybio.life.

More on Ohio Pen

• Keyanb Exchange Implements Enhanced Security Protocols Amid Industry-Wide Trust Challenges
• TSWHZC Platform Combines Automated Portfolio Management with Proof of Reserves for Brazil Market Entry
• AureaVault Positions Digital Asset Infrastructure for Shifting Monetary Policy Environment
• JQRBT Unveils High-Speed Trading Infrastructure Designed for Growing Institutional Crypto Market
• Hammes celebrates the opening of the Franklin County Crisis Care Center in Columbus, Ohio

About Journey Biosciences

Journey Biosciences is a US-based biotechnology company dedicated to fundamentally improving diabetes care. We are focused on identifying blood-based predictive biomarkers and developing clinically validated, laboratory developed tests (LDTs) that identify and rate a person's risk level for developing complications from diabetes. Learn more at www.journeybio.life.

Know Your Risk. Change Your Life. ™

To access the Journey Biosciences media kit, visit journeybio.life/media

SOURCE Journey Biosciences, Inc.

---

Show All News | Report Violation